Anticlotting drug found to be safe in sickle cell patientsOctober 12, 2007CHAPEL HILL - An intravenous "blood thinner" widely used in patients with acute coronary syndromes and during coronary artery stent placement appears to be safe in patients with sickle cell disease and may have beneficial anti-inflammatory effects, a small study at the University of North Carolina at Chapel Hill School of Medicine has found. "We have tested a potentially promising drug in sickle cell patients, and the drug appears to be well tolerated. This gives us the impetus to go ahead with further studies of eptifibatide in these patients," said Dr. Leslie V. Parise, department chair and professor of biochemistry and biophysics at the UNC-Chapel Hill School of Medicine. The hallmark of sickle cell disease is malformed red blood cells that can cause sudden painful episodes when they block small blood vessels. However, sickle cell patients are also at increased risk of developing multiple other complications, including strokes, lung complications and pulmonary hypertension.
The most frequent manifestations of sickle cell disorders are anemia and pain episodes. The episodic exacerbation of pain, often called "crises," is unpredictable and may occur often in some patients. The only drug presently approved for the treatment of sickle cell disease is hydroxyurea, which has been shown to reduce the frequency of painful episodes. Parise emphasized the need for further study. "We did not test this drug in patients who are in crisis, and we cannot recommend that doctors prescribe this drug for sickle cell patients at this time," she said. The results of the study were published online (Oct. 6) in the British Journal of Haematology. The researchers gave intravenous infusions of eptifibatide (brand name Integrilin) to four patients with sickle cell anemia who were not experiencing pain episodes. "They did well clinically. They did not experience any deleterious changes in their blood tests or have a pain episode," said coauthor Dr. Kenneth I. Ataga, assistant professor of medicine at UNC-Chapel Hill. In the current study, blood tests showed that while the patients' liver, kidney and other functions remained at baseline, several indicators of inflammation decreased, including levels of a protein called CD40L known to play a role in inflammation and in blood clotting. Previous studies conducted by Sheritha Lee a graduate student in Parise's lab showed that patients with sickle cell disease have CD40L levels that are as much as 30 times higher than in patients without the disease. Eptifibatide's known ability to decrease CD40L led the researchers to study whether the drug might help sickle cell patients. University of North Carolina at Chapel Hill Science News and Science Current Events Tag Cloud This tag cloud is a visual representation of term frequencies of random science news topics with common terms grouped together and emphasized by their display size. Condom Use Mass Extinction Sleep Deprivation Huntingtons Disease Big Bang Twins Preeclampsia Alcohol Dependence Gamma-ray Burst Oral Contraceptive Asthma Invasive species Bipolar Disorder Back Pain Lithium Cloning Coral reef Atmosphere Climate Warming Alcoholism DNA repair Plate Tectonics Titanium Dioxide Protons Working Memory
See More: Science News Tags | |||||||||||||||||||||
|
Related Sickle Cell Current Events and Sickle Cell News Articles Children's Hospital Oakland scientists first to discover new source for harvesting stem cells A groundbreaking study conducted by Children's Hospital & Research Center Oakland is the first to reveal a new avenue for harvesting stem cells from a woman's placenta, or more specifically the discarded placentas of healthy newborns. Embryo's heartbeat drives blood stem cell formation Biologists have long wondered why the embryonic heart begins beating so early, before the tissues actually need to be infused with blood. Simulated gene therapy In a recent issue of The Journal of Chemical Physics, published by the American Institute of Physics (AIP), a group of researchers at the University of California, Berkeley and Los Alamos National Laboratory describe the first comprehensive, molecular-level numerical study of gene therapy. Screening to help prevent stroke in kids increases, but limited access a problem The number of children with a certain blood disorder undergoing an ultrasound to help prevent stroke is up significantly in the past 10 years since the publication of a major study showing its benefits. New guidelines for prescribing opioid pain drugs published A prestigious panel of pain-management experts representing the American Pain Society (APS) www.ampainsoc.org and the American Academy of Pain Medicine (AAPM) has published the first comprehensive clinical practice guideline to assist clinicians in prescribing potent opioid pain medications for patients with chronic non-cancer pain. New guideline for prescribing opioid pain drugs published A national panel of pain management experts representing the American Pain Society (APS) and the American Academy of Pain Medicine (AAPM) has published the first comprehensive, evidence-based clinical practice guideline to assist clinicians in prescribing potent opioid pain medications for patients with chronic non-cancer pain. UC HEALTH LINE: Spirituality May Help Adolescents Cope With Chronic Illness Chronic illness can lead to poorer quality of life-particularly for adolescents. New research shows that spirituality may help teens cope with their conditions. Studies examine quality of care for hospitalized sickle cell disease patients A study assessing the quality of care for patients with sickle cell disease in a variety of hospital settings will be presented at a press conference on Saturday, December 6, at 9:30 a.m., during the 50th Annual Meeting of the American Society of Hematology in San Francisco, CA. Ultrasound screening helps prevent stroke in children with sickle cell disease Screening with an ultrasound machine has proved highly successful in preventing stroke among children with sickle cell disease, by identifying children who are then preventively treated with blood transfusions. Gene therapy corrects sickle cell disease in laboratory study Using a harmless virus to insert a corrective gene into mouse blood cells, scientists at St. Jude Children's Research Hospital have alleviated sickle cell disease pathology. More Sickle Cell Current Events and Sickle Cell News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||